Breast Clinical Trials

Study Name: (CAPItello-292)

• Description: Capivasertib + CDK4/​6i + Fulvestrant for Advanced/​Metastatic HR+/​HER2- Breast Cancer (CAPItello-292)
• Study Number: D361DC00001
• FHH or Referral: Referral
• NCT#: NCT04862663
• Cancer Stage: IV
• Key Inclusion: HR+/HER2-

For more information, call XXX